SELLAS Life Sciences (SLS) Gross Profit (2012 - 2022)

SELLAS Life Sciences (SLS) has reported Gross Profit for 7 consecutive years, with $900000.0 the latest figure, recorded in Q1 2022.

• In Q1 2022, Gross Profit fell 83.93% year-over-year to $900000.0; the TTM figure through Dec 2022 stood at $900000.0 (down 87.84% YoY), while the FY2022 annual figure was $900000.0, down 87.84% from the prior year.
• Gross Profit fell to $900000.0 in Q1 2022 per SLS's latest filing, from $1.8 million in the prior quarter.
• Across five years, Gross Profit topped out at $5.6 million in Q1 2021 and bottomed at $900000.0 in Q1 2022.
• Historically, Gross Profit has averaged $2.6 million across 3 years, with a median of $1.8 million in 2020.
• On a YoY basis, Gross Profit climbed as much as 83.93% in 2022 and fell as far as 83.93% in 2022.
• SELLAS Life Sciences' Gross Profit stood at $1.9 million in 2020, then decreased by 5.26% to $1.8 million in 2021, then slumped by 50.0% to $900000.0 in 2022.
• Business Quant data shows SLS's Gross Profit at $900000.0 in Q1 2022, $1.8 million in Q2 2021, and $5.6 million in Q1 2021.